Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

DxVx, Won the Governmental Project to Develop Diagnostic Sensor Kit for Adult Diseases

DxVx announced today that it won the national project, ‘Korea-led K-Sensor Technology Development for Market Leadership’ supported by the Ministry of Trade, Industry and Energy and managed by the Korea Evaluation Institute of Industrial Technology.

The main task is ‘Development of optical sensor system for early diagnosis of adult diseases based on biomarkers in urine’, which is to discover biomarkers (biochemical substances such as volatile organic compounds and glucose) in urine for full-time monitoring and early diagnosis of various adult diseases such as diabetes and prostate cancer. It also aims to develop an in vitro POCT (point-of-care device) capable of measuring various biomarkers by applying MEMS (microelectromechanical system) technology, optical technology, semiconductor technology for signal processing, and artificial intelligence analysis technology.

In this project, which will be carried out over three years with a total budget of about $3.6 million($2.8 million in government support), Dx&Vx will lead the development as a lead company. It will be developed in collaboration with the Korea Electronics Technology Institute (KETI), the Department of Urology at Hanyang University College of Medicine, and the Department of Electrical and Electronics Engineering at Korea University. COREE Group will be responsible for final commercializing.

With winning of this project, Dx&Vx expects to further accelerate its total biohealthcare solution business. In particular, after product development, Dx&Vx plans to launch the product in China through its Chinese subsidiary company and global sales through COREE Group’s overseas network, which is expected to increase its sales and grow the in vitro diagnostic business.

“Starting with the diagnostic development business that combines biotechnology and semiconductors, we will expand the development of additional modules using AI and IoT technologies, data analysis algorithms, and technologies for early diagnosis,” said an official from Dx&Vx. “We will solve the unmet need for early diagnosis of various adult diseases and bio healthcare problems due to the global aging trend, and provide total healthcare solutions using micro-system semiconductors for diagnosis and therapeutic management.”

The products to be developed in the future are expected to be utilized for various adult diseases such as diabetes, hypertension, prostate cancer, and bladder cancer, and will be presented in the form of a non-invasive ‘POCT equipment and cartridges, a sensor system for early diagnosis of adult diseases’.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy